Foundations of an Ovine Model of Fragile X Syndrome

Read full text
Authors: Victoria Hawkins, Skye R. Rudiger, Clive J. McLaughlan, Jennifer M. Kelly, Klaus Lehnert, Jessie C. Jacobsen, Renée R. Handley, Kimiora Henare, Paul John Verma, Russell Grant Snell
Cited by: 1
References: 40

Abstract

BACKGROUND: Fragile X Syndrome (FXS) is an X-linked neurodevelopmental disorder characterised by intellectual disability, developmental delays, anxiety, and social and behavioural challenges. Currently, no effective treatments exist to address the root cause of FXS. Mouse models are the most widely used for studying molecular pathogenesis and conducting preclinical treatment testing. However, therapeutic interventions that show promise in rodent models have yet to succeed in clinical trials. After evaluating the current models, we have developed an ovine model to address this clinical translation gap. We expect this model to more accurately reflect the human condition in brain size, structure, and neurodevelopmental trajectory. We aim to establish this model as a valuable preclinical platform for testing therapies for FXS. METHODS: gene in ovine embryos. RESULTS: gene knockouts. The ewe carries inactivating mutations on both alleles, with the edits in both animals resulting in no detectable Fragile X Messenger Ribonucleoprotein (FMRP) as expected. Both founders have undergone molecular characterisation and basic health checks, with the female founder showing increased joint flexibility, a characteristic of FXS. The ram has been used for breeding, with the successful transmission of the edited allele to his offspring. Importantly, specific lamb cohorts for postnatal treatment testing can be produced efficiently utilising accelerated breeding methods and preimplantation selection.

Fields of Study & Subjects

Genetics and Neurodevelopmental Disorders Ubiquitin and proteasome pathways Neurogenetic and Muscular Disorders Research

Publication details

Journal / source
Genes
Publisher
MDPI AG
Volume
17
Issue
2
Pages
152–152
Publication date
28 January 2026
Language
EN